Opioids provide modest short-term relief for some types of nerve pain, but the evidence behind that relief is surprisingly thin, and most clinical guidelines now place opioids well below other treatments in the recommended order. A large Cochrane review found that roughly half of patients given an opioid for neuropathic pain achieved at least a third reduction in pain intensity, but the studies driving that number were small, short, and designed in ways likely to inflate the benefit. Nerve pain also responds less reliably to opioids than other kinds of pain, for biological reasons that matter when you’re weighing risks against potential payoff.
What the Trial Evidence Actually Shows
The most cited overview of opioid trials in neuropathic pain pooled fourteen studies covering about 845 participants. On average, each study enrolled only around 60 people, and most lasted less than six weeks. Under those conditions, about 57% of opioid-treated participants reported at least a third reduction in pain, compared with 34% on placebo. That translates to needing to treat roughly four patients for one extra person to get that level of relief beyond what a sugar pill would provide. When the bar was raised to 50% pain relief, about 47% of opioid users hit it versus 30% on placebo, and the number needed to treat climbed to about six.1PubMed Central. Opioids for neuropathic pain
Those numbers sound reasonable until you look at the study quality. The review’s authors specifically noted that the trials were “predominantly with features likely to overestimate treatment effects”: they were small, short, and used statistical methods for handling dropouts that tend to make a drug look better than it is. A separate Cochrane review focusing only on morphine concluded there was “insufficient evidence to support or refute the suggestion that morphine has any efficacy in any neuropathic pain condition.”2PubMed Central. Morphine for chronic neuropathic pain in adults So the honest summary is that opioids probably help some people with nerve pain in the short run, but we do not have strong, long-duration evidence to say how much or for how long.
Why Nerve Pain Responds Differently to Opioids
Opioids work mainly by binding to mu-opioid receptors on nerve cells in the brain and spinal cord, dampening pain signals. That mechanism works well for “nociceptive” pain, the kind you get from a broken bone or surgical wound, where the signals travel along intact pathways. Nerve pain is fundamentally different. It arises from damage to the nerves themselves, which rewires signaling in ways that can actually interfere with how opioids do their job. Pain researchers have observed that the same biological changes responsible for generating neuropathic pain can simultaneously blunt the painkilling properties of opioids.3PubMed. Opioids and neuropathic pain
Diabetic neuropathy offers a clear example of this problem. In animal studies, diabetes causes sensory neurons to lose mu-opioid receptors from their surfaces, literally pulling them into the interior of the cell and breaking them down. The result is that higher opioid doses are needed to produce any meaningful pain relief, which brings more side effects and a steeper path toward tolerance.4PubMed Central. Rab7 silencing prevents μ-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy This biological quirk helps explain why many patients with nerve pain find opioids less effective than expected, or find that an initially helpful dose stops working relatively quickly.
Adding another layer of difficulty, the mechanisms behind opioid-induced hyperalgesia, a paradoxical state where opioids themselves start increasing pain sensitivity, overlap with the mechanisms that generate neuropathic pain in the first place.5PubMed. Effect of prior treatment with ultra-low-dose morphine on opioid- and nerve injury-induced hyperalgesia in rats In other words, there is a biological reason why nerve pain patients may be especially vulnerable to the phenomenon of opioids making pain worse over time rather than better.
Where Opioids Fall in Treatment Guidelines
Given the weak evidence base and the biological headwinds, most clinical guidelines now recommend trying several other treatment classes before turning to opioids. Antidepressants such as duloxetine and certain older tricyclics, along with anticonvulsants like gabapentin and pregabalin, are widely considered first-line options.6PubMed. The treatment of neuropathic pain: antidepressants and opioids These drugs were not developed for pain, but they target the central nervous system pathways that misfire in neuropathic conditions, and their evidence base, while imperfect, is stronger and longer-term than what exists for opioids.
A comprehensive algorithm published in Pain Medicine recommends opioids no earlier than fourth-line therapy, after antidepressants, anticonvulsants, topical treatments, and even neurostimulation have been tried.7PubMed Central. A Comprehensive Algorithm for Management of Neuropathic Pain French neuropathic pain guidelines similarly reserve strong opioids for third-line use, explicitly noting they should be considered only “in the lack of alternative.”8PubMed. French guidelines for neuropathic pain: An update and commentary The tramadol exception is worth knowing about: because tramadol is weaker and has a somewhat different mechanism, some guidelines place it a tier higher than morphine or oxycodone, as a second-line option alongside combination therapies.9PubMed. Neuropathic pain: Evidence based recommendations
The Gap Between Guidelines and Real-World Prescribing
Despite their low ranking in official recommendations, opioids remain among the most commonly prescribed treatments for nerve pain in practice. A study of commercially insured patients with diabetic peripheral neuropathy found that opioids were the single most common first-line treatment, prescribed to about a third of patients receiving any medication for the condition. By contrast, the FDA-approved agents duloxetine and pregabalin were used as first-line therapy in a combined total of less than 7% of patients.10PubMed Central. Opioid Use in the Management of Diabetic Peripheral Neuropathy (DPN) in a Large Commercially Insured Population About a fifth of those patients used opioids exclusively, with no other pain medications at all.
A similar pattern shows up in postherpetic neuralgia, the chronic nerve pain that can follow a shingles outbreak. Opioids were the most frequently prescribed initial treatment at roughly 22%, ahead of gabapentin at 15% and lidocaine patches at 8%. Patients started on opioids also incurred the highest additional healthcare costs, averaging over $7,600 more per year than matched patients without the condition.11PubMed Central. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia The study’s authors noted that medications supported by evidence as first-line therapies were “underused relative to opioid-based therapies across all ages.” That gap between what the evidence supports and what actually gets prescribed is one of the most important things to understand about opioids and nerve pain.
Dual-Mechanism Opioids and Why They Get Attention
Tapentadol and tramadol are sometimes discussed as if they are a different category of treatment, and there is a kernel of truth to that. Both drugs combine traditional opioid activity with a second mechanism: they block the reuptake of norepinephrine, a neurotransmitter that plays a role in the body’s own pain-suppression pathways. The norepinephrine component is the same pathway that makes antidepressants like duloxetine useful for nerve pain, so in theory these drugs attack the problem from two angles simultaneously.12PubMed Central. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings
Animal research on tapentadol has shown that its two mechanisms work together synergistically in neuropathic pain models, producing pain relief comparable to morphine or oxycodone but with a more tolerable side-effect profile.13PubMed Central. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy The clinical picture is less encouraging, though. A narrative review comparing tapentadol and tramadol found that the overall level of evidence for both drugs in chronic pain is “globally low,” and that tapentadol “does not provide a clinically significant analgesic improvement compared to existing treatments, for which the safety profile is much better known.”14PubMed Central. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients The concept is biologically promising, but the clinical trials have not yet delivered evidence strong enough to change how these drugs rank against established first-line therapies.
Combining Opioids with Gabapentin or Pregabalin
If opioids alone are modestly helpful and gabapentin alone is modestly helpful, what about using both together? This is one area where the evidence is genuinely encouraging. A well-known crossover trial gave participants with neuropathic pain four regimens in random order: placebo, gabapentin alone, morphine alone, and the two together. Average daily pain on a 0-to-10 scale was about 4.5 on placebo, 4.2 on gabapentin, 3.7 on morphine, and 3.1 on the combination. The combination beat each drug individually by a statistically meaningful margin, and the doses needed of each drug were lower when they were paired.15PubMed. Morphine, gabapentin, or their combination for neuropathic pain The tradeoff was more constipation than gabapentin alone and more dry mouth than morphine alone.
In cancer patients specifically, the combination approach has shown clearer advantages. A meta-analysis pooling seven studies found that adding gabapentin to opioids significantly reduced pain intensity in neuropathic cancer pain beyond what opioids achieved on their own.16PubMed Central. The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis A randomized trial in the same population found that the combination provided better relief specifically for burning and shooting pain qualities, and that the gabapentin-opioid group actually experienced fewer side effects than the opioid-only group.17PubMed. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial Pregabalin, gabapentin’s close relative, showed a similar early benefit when added to opioids for nerve pain in cervical myelopathy patients, though the advantage faded after the first four weeks and side effects accumulated with longer use.18PubMed. Comparison of the use of opioids only and pregabalin add-on for the treatment of neuropathic pain in cervical myelopathy patients: a pilot trial
The combination data suggest that if opioids have a role in nerve pain, it may be as one part of a multi-drug regimen rather than as a standalone treatment. Lower doses of each drug can reduce side effects while still producing meaningful pain relief. For cancer patients whose pain involves nerve damage, this approach has the strongest support.
Why Long-Term Use Tends to Disappoint
The trial evidence for opioids in nerve pain comes almost entirely from studies lasting twelve weeks or less, and most lasted under six weeks. That is a problem because neuropathic pain is usually chronic, lasting months or years. A narrative review of long-term opioid use for chronic non-cancer pain found that early improvements in function and quality of life “are typically not sustained.” Patients reported more satisfaction with their care in the short term, but that satisfaction faded as tolerance developed and doses had to escalate.19PubMed Central. Adverse Events of the Long-Term Use of Opioids for Chronic Non-cancer Pain: A Narrative Review
Tolerance is a particular concern with nerve pain. Because the biological basis of neuropathic pain already impairs opioid receptor function, patients may be starting from a disadvantaged position, needing higher doses sooner and facing a steeper escalation curve. As doses climb, so do constipation, sedation, hormonal disruption, and the risk of dependence. The absence of good long-term efficacy data is one of the main reasons guidelines push opioids so far down the treatment ladder. The drugs were never convincingly shown to help over the timeframes that nerve pain actually persists.
The Misuse Risk Factor
Prescribing opioids for a chronic condition that responds poorly to them creates a setup for escalating use and, in some patients, misuse. Research using brain imaging has found that chronic pain patients at higher risk for opioid misuse show differences in their endogenous opioid systems, specifically higher baseline availability of mu-opioid receptors in the amygdala compared with lower-risk patients.20PubMed Central. Risk for opioid misuse in chronic pain patients is associated with endogenous opioid system dysregulation This is not a character flaw; it reflects brain chemistry that predisposes some individuals to develop problematic patterns of opioid use, especially when the drug provides incomplete pain relief and the temptation to increase the dose is constant.
The cost data from postherpetic neuralgia reinforces this concern from a different angle. Patients started on opioids incurred substantially higher healthcare spending than those started on other therapies, and that cost gap likely reflects both the need for escalating treatment and the downstream complications of long-term opioid use.11PubMed Central. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia When a treatment works well, costs tend to stabilize. When it works poorly and patients keep chasing relief, costs climb.
Nerve Pain from Chemotherapy
Chemotherapy-induced peripheral neuropathy deserves a separate mention because it is common, often severe, and has almost no approved treatments. Drugs like oxaliplatin and paclitaxel damage peripheral nerves as an unintended consequence of killing cancer cells, leaving patients with burning, tingling, or shooting pain in the hands and feet that can persist long after treatment ends. Interesting basic science work has shown that blocking mu-opioid receptors in the spinal cord can actually prevent and reverse the pain caused by these drugs in animal models, which suggests the opioid system is directly involved in generating this type of neuropathic pain, not just modulating it.21PubMed. Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy That is a counterintuitive finding and complicates the straightforward notion that activating opioid receptors should help. The relationship between opioids and nerve pain is clearly more tangled than “opioids block pain signals.”
Alternatives That Have Gained Ground
Spinal cord stimulation has become an increasingly established option for neuropathic pain that does not respond to medications. The technique involves implanting small electrodes near the spinal cord that deliver electrical pulses to interrupt pain signals before they reach the brain. It has been used for over forty years and has shown favorable cost-effectiveness compared with long-term drug therapy, yet remains underused by general practitioners and neurologists alike.22PubMed Central. Spinal Cord Stimulation for Neuropathic Pain: Current Trends and Future Applications Patients typically considered for spinal cord stimulation are those who have already failed multiple medication trials, and the risk-to-benefit ratio is considered favorable for this population.23PubMed. Spinal cord stimulation for neuropathic pain
Some guidelines now recommend a trial of spinal cord stimulation before resorting to strong opioids, reversing the older assumption that devices should be saved for last. For certain conditions like failed back surgery syndrome or complex regional pain syndrome, spinal cord stimulation has a stronger evidence base than opioid therapy and avoids the systemic side effects that come with taking a medication every day.
Cannabinoid research has also generated interest. In an animal model of chronic neuropathic pain, orally consumed THC and CBD both reduced allodynia over a three-week period, while tolerance to morphine developed after just one week.24PubMed Central. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain Translating mouse findings to human clinical use requires caution, but the contrast in tolerance timelines is striking and has motivated further clinical research. For a condition where the biggest practical problem with opioids is that they stop working, a substance that maintains its effect over weeks rather than days is worth investigating seriously.
Postherpetic Neuralgia and the Question of Specific Conditions
The answer to whether opioids work for nerve pain depends partly on which nerve pain you are talking about. Postherpetic neuralgia, the pain that lingers after shingles, is one condition where opioids have earned at least a mention alongside other established therapies. A review of treatment options identified opioids as one of several agents with proven efficacy in controlled trials, alongside the lidocaine patch, gabapentin, and tricyclic antidepressants, recommending an approach that selects from agents with “complementary mechanisms of action.”25PubMed. Treatment of postherpetic neuralgia: a review of therapeutic options The practical limitation, as noted earlier, is that real-world prescribing defaults heavily to opioids at the expense of better-supported first-line options, and patients started on opioids end up costing the healthcare system substantially more.
Diabetic neuropathy is a harder case. The biological impairment of opioid receptors in diabetes means that higher doses are needed, side effects increase, and the risk-to-benefit calculation tilts unfavorably. Yet opioids remain the most commonly prescribed first-line treatment for the condition in practice. That disconnect between biology, evidence, and prescribing habits is one of the clearest examples of why the question “do opioids work for nerve pain” cannot be answered with a simple yes or no. They can work, partially and temporarily, in some conditions more than others, but the cases where they make sense as a primary strategy are narrow and getting narrower as alternatives improve.